GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,600.00p
   
  • Change Today:
    -4.50p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,144.96m
  • Volume: 3,788,158
  • Market Cap: £66,319m
  • RiskGrade: 129

Citi puts GSK on 'positive catalyst watch', cites Zantac litigation developments

By Michele Maatouk

Date: Friday 26 Aug 2022

LONDON (ShareCast) - (Sharecast News) - Citigroup put pharmaceuticals company GlaxoSmithKline on "positive catalyst watch" on Friday as it pointed to legal developments related to the company's now-discontinued Zantac heartburn drug.
The bank pointed to legal developments that it said could "materially reduce" GSK' exposure versus the $17bn being discounted.

"We note a tentative ruling by Judge Rosenberg who is presiding over the multidistrict litigation could leave up to 70,000 US Zantac plaintiffs (that are being forced to exit the MDL) with insufficient time to find legal representation to file in a state court before the statute of limitations prevents them from prosecuting their claim," Citi said in a note.

"If this plays out, the eventual plaintiff pool could be materially lower than the market fears.

"Any likely settlement much closer to $10bn versus the combined $50bn of market cap that has been wiped off for the various defendants."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,600.00p
Change Today -4.50p
% Change -0.28 %
52 Week High 1,812.50
52 Week Low 1,316.00
Volume 3,788,158
Shares Issued 4,144.96m
Market Cap £66,319m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
55.44% below the market average55.44% below the market average55.44% below the market average55.44% below the market average55.44% below the market average
37.25% above the sector average37.25% above the sector average37.25% above the sector average37.25% above the sector average37.25% above the sector average
Price Trend
33.91% above the market average33.91% above the market average33.91% above the market average33.91% above the market average33.91% above the market average
54.72% above the sector average54.72% above the sector average54.72% above the sector average54.72% above the sector average54.72% above the sector average
Income
16.31% above the market average16.31% above the market average16.31% above the market average16.31% above the market average16.31% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
20.4% below the market average20.4% below the market average20.4% below the market average20.4% below the market average20.4% below the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average

What The Brokers Say

Strong Buy 8
Buy 4
Neutral 10
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 16-May-24 22-Feb-24
Paid 11-Jul-24 11-Apr-24
Amount 15.00p 16.00p

Trades for 17-Jun-2024

Time Volume / Share Price
16:50 2,189 @ 1,600.00p
16:47 3,937 @ 1,597.05p
16:35 20,000 @ 1,599.06p
16:35 10,941 @ 1,600.00p
16:35 9,836 @ 1,600.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page